このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Smith & Nephew 配当金

配当金基準チェック /36

Smith & Nephewは配当を支払う会社で、現在の利回りは2.47%です。次の支払い日は 8th November, 2024で、権利落ち日は4th October, 2024 。

主要情報

2.4%

配当利回り

107%

配当性向

業界平均利回り	1.7%
次回配当支払日	08 Nov 24
配当落ち日	04 Oct 24
一株当たり配当金	US$0.375
一株当たり利益	US$0.35
配当利回り予想	3.0%

最近の配当金アップデート

Recent updates

配当金の支払いについて

決済の安定と成長

配当データの取得

安定した配当: SNNの1株当たり配当金は過去10年間安定しています。

増加する配当: SNNの配当金は過去10年間にわたって増加しています。

配当利回り対市場

Smith & Nephew 配当利回り対市場

SNN 配当利回りは市場と比べてどうか？
セグメント	配当利回り
会社 (SNN)	2.4%
市場下位25% (US)	1.4%
市場トップ25% (US)	4.3%
業界平均 (Medical Equipment)	1.7%
アナリスト予想 (SNN) (最長3年)	3.0%

注目すべき配当: SNNの配当金 ( 2.99% ) はUS市場の配当金支払者の下位 25% ( 1.53% ) よりも高くなっています。

高配当: SNNの配当金 ( 2.99% ) はUS市場の配当金支払者の上位 25% ( 4.81% ) と比較すると低いです。

株主への利益配当

収益カバレッジ: SNNは高い配当性向 ( 124.2% ) のため、配当金の支払いは利益によって十分にカバーされていません。

株主配当金

キャッシュフローカバレッジ: SNNは高い現金配当性向 ( 180.7% ) のため、配当金の支払いはキャッシュフローで十分にカバーされていません。

Smith & Nephew 配当金

配当金 基準チェック /36

主要情報

最近の配当金アップデート

Smith & Nephew plc Announces Final Dividend of the Year Ended 31 December 2023, Payable on May 22, 2024

Smith & Nephew plc Recommends Final Dividend for 2023, Payable on May 22, 2024

Smith & Nephew plc Announces Interim Dividend for 2023, Payable 1 November 2023

Recent updates

Smith+Nephew Announces Board and Committee Changes

Smith & Nephew Delivering On Its Turnaround Promise

Smith & Nephew plc Provides Revenue Guidance for the Second Half and Reaffirms Earnings Guidance for the Year 2024

Smith+Nephew Announces 510(K) Clearance of New Catalysystem Primary Hip System

Cevian Capital II GP Limited acquired 5.02% stake in Smith & Nephew plc (LSE:SN.).

Smith & Nephew: Work To Be Done But Still Long-Term Potential

Smith & Nephew plc Announces Final Dividend of the Year Ended 31 December 2023, Payable on May 22, 2024

Smith & Nephew plc to Report First Half, 2024 Results on Aug 01, 2024

Smith+Nephew Introduces the RENASYS EDGE Negative Pressure Wound Therapy System

Smith & Nephew plc Announces Board Changes

Smith & Nephew plc, Annual General Meeting, May 01, 2024

Smith & Nephew plc Recommends Final Dividend for 2023, Payable on May 22, 2024

Smith+Nephew Announces Commercial Launch of Its Aetos Shoulder System for Anatomic and Reverse Shoulder Replacement At Aaos 2024 Annual Meeting

Smith & Nephew plc Announces Standout Results for Its Regeneten Bioinductive Implant from A Recently Completed Randomized Controlled Trial

Smith & Nephew plc (LSE:SN.) acquired CartiHeal (2009) Ltd.

Smith & Nephew: Orthopedics Growth Continues To Drive Sales Forward

Smith+Nephew Announces Board Changes

Smith+Nephew Announces Board Changes

Smith & Nephew plc (LSE:SN.) entered into a definitive agreement to acquire CartiHeal (2009) Ltd. for $330 million.

Smith & Nephew plc Provides Earning Guidance for Full Year 2023

Smith & Nephew plc Announces Appointment of John Rogers as CFO

Smith & Nephew plc Announces Interim Dividend for 2023, Payable 1 November 2023

Smith & Nephew Getting More Interesting As A Contrarian Idea

Smith & Nephew plc Announces Board and Committee Changes

Smith & Nephew plc Increases Revenue Guidance for 2023

Smith & Nephew plc Announces Step Down of Anne-Françoise Nesmes as Chief Financial Officer

Smith & Nephew: Entering New Markets But Growth Is Slow Still

Smith+Nephew Announces 510(K) Clearance of its AETOS Shoulder System

Smith & Nephew reports FY earnings; initiates FY23 guidance

Smith & Nephew plc, Annual General Meeting, Apr 26, 2023

Smith & Nephew: Potential Only Has Value If You Can Execute

Smith & Nephew plc to Report Fiscal Year 2022 Results on Feb 21, 2023

Smith & Nephew plc Announces Revenue Guidance for 2022

Smith+Nephew Expands Procedural Innovation with Introduction of JOURNEY(TM) II ROX(TM) Total Knee Solution

Smith+Nephew First to Market with Revision Knee Indication on Robotics Platform

Smith & Nephew: Still A Buy Despite Short-Term Challenges

Smith+Nephew Launches OR3O ™ Dual Mobility System in Japan for Use in Primary and Revision Hip Arthroplasty

Smith+Nephew Announces New Data Furthering a Number of Published Studies Supporting the Use of Its REGENETEN Bioinductive Implant in Rotator Cuff Repair

Smith & Nephew plc to Report Q2, 2023 Results on Aug 03, 2023

Smith & Nephew plc Announces Executive Changes

Smith & Nephew plc Provides Revenue Guidance for the Second Half and Full Year of 2022

Smith &amp; Nephew 1H 2022 Earnings Preview

Smith+Nephew Launches Clinical Support App to Help Reduce Practice Variation in Wound Care

Smith+Nephew launches app Wound Compass to help reduce variation in wound care

Smith & Nephew plc Announces Executive Changes

Smith & Nephew plc Announces Executive Changes

Smith+Nephew Announces First Total Hip Replacement Cases on its CORI Surgical System Using RI.HIP Modeler and RI.HIP Navigation

Smith & Nephew: Fair Price For An Attractive Medical Devices Supplier

Smith+Nephew Announces New Study Showing GRAFIX™ Membrane Cut the Rate of Diabetic Foot Ulcer Recurrence in Half Compared to Leading Competitors

Smith & Nephew plc, Annual General Meeting, Apr 13, 2022

Smith & Nephew plc Provides Revenue Guidance for the Second Half and Year of 2022

Smith+Nephew Expands Next-Generation Handheld Robotic-Assisted CORI™ Surgical System into Total Hip Arthroplasty with RI.HIP NAVIGATION

Smith & Nephew: Valuation Looking More Attractive

Smith+Nephew Announces New Indications for Use for its PICO 7 and PICO 14 Single Use Negative Pressure Wound Therapy Systems

Smith & Nephew plc (LSE:SN.) acquired Engage Surgical.

Smith & Nephew plc (LSE:SN.) announces an Equity Buyback for $300 million worth of its shares.

Smith+Nephew Launches Real Intelligence and CORI Surgical System and Next Generation Handheld Robotics Platform in Canada

Smith+Nephew Launches CORI Handheld Robotics

Smith & Nephew Is A Premium Brand That Should Deliver Something Special

Smith & Nephew Leveraged To Post-Pandemic Normalization And Self-Help

Smith+Nephew Introduces Pioneering New Technologies for Its Journey II Total Knee Arthroplasty Portfolio

Smith+Nephew Announces Launch of WEREWOLF FASTSEAL 6.0 Hemostasis Wand

Smith+Nephew Announces Study Results Showing Patients Treated with Just its REGENETEN Bioinductive Implant for Partial-Thickness Rotator Cuff Tears

Smith & Nephew plc: Improving Performance Reflected In Price

Smith+Nephew Launches ARIA Home PT, a Remote Physical Therapy Solution

Smith & Nephew plc Provides Revenue Guidance for the Full Year 2021

Smith+Nephew's ALLEVYN™ LIFE Foam Dressings Halved Change Frequency, Significantly Reduced Cost and Improved Treatment Satisfaction in Real-World Study

Net Health Adds Smith+Nephew's RENASYS GO Negative Pressure Wound Therapy System to Net Health® Wound Care Connections Lineup

Smith & Nephew plc, Annual General Meeting, Apr 14, 2021

Smith & Nephew plc Announces Appointment of John Ma as Non-Executive Director, Effective 17 February 2021

Smith & Nephew: Pandemic Long Tail Reduces Attractiveness

Smith+Nephew Partners with Movemedical to Streamline Inventory Management and Improve Customer Experience

配当金基準チェック /36

Smith & Nephew 1H 2022 Earnings Preview